Related Experiment Video
Updated: Oct 9, 2025
A Human Glioblastoma Organotypic Slice Culture Model for Study of Tumor Cell Migration and Patient-specific Effects of Anti-Invasive Drugs
Published on: July 20, 2017
Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma
Robert Cornelison1, Laine Marrah1, Drew Horter1
1Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Abstract:
Glioblastoma (GBM) is the most common adult neural malignancy and the deadliest. The standard of care is optimal, safe, cytoreductive surgery followed by combined radiation therapy and alkylating chemotherapy with temozolomide. Recurrence is common and therapeutic options in the recurrent setting are limited. The dismal prognosis of GBM has led to novel treatments being a serious roadblock in the field, with most new treatments failing to show efficacy. Targeted therapies have shown some success in many cancers, but GBM remains one of the most difficult to treat, especially in recurrence. New chemotherapeutic directions need to be explored, possibly expanding the targeted chemotherapy spectrum in previously unforeseen ways. In this perspective paper, we will explain why AVIL, an actin-binding protein recently found to be overexpressed in GBM and a driving force for GBM, could prove versatile in the fight against cancer. By looking at AVIL and its potential to regulate FOXM1 and LIN28B, we will be able to highlight a way to improve outcomes for GBM patients who normally have very little hope.
Insights
Glioblastoma (GBM) is a deadly brain cancer. Targeting the overexpressed protein AVIL may offer a new therapeutic strategy, potentially regulating FOXM1 and LIN28B to improve patient outcomes.
Area of Science:
- Neuro-oncology
- Cancer biology
- Molecular medicine
Background:
- Glioblastoma (GBM) is the most aggressive primary brain tumor with limited treatment options.
- Recurrent GBM presents significant therapeutic challenges, necessitating novel treatment strategies.
- Current targeted therapies have shown limited success in GBM, especially upon recurrence.
Purpose of the Study:
- To explore the potential of AVIL, an actin-binding protein, as a novel therapeutic target in Glioblastoma.
- To investigate the role of AVIL in GBM pathogenesis and its potential to regulate key oncogenic pathways.
- To highlight a new therapeutic avenue for improving outcomes in GBM patients.
Main Methods:
- This perspective paper reviews existing literature on AVIL, FOXM1, and LIN28B in the context of Glioblastoma.
- Analysis of AVIL's function as an actin-binding protein and its overexpression in GBM.
- Exploration of AVIL's regulatory interactions with FOXM1 and LIN28B.
Main Results:
- AVIL is identified as an overexpressed protein and a potential driving force in Glioblastoma.
- AVIL's actin-binding properties suggest a role in GBM cell motility and invasion.
- AVIL's potential to regulate FOXM1 and LIN28B indicates a promising molecular target.
Conclusions:
- AVIL represents a versatile and promising therapeutic target for Glioblastoma treatment.
- Targeting AVIL could offer a novel strategy to overcome therapeutic resistance in recurrent GBM.
- Further research into AVIL-targeted therapies may significantly improve Glioblastoma patient prognosis.
More Related Videos
10:28Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Published on: January 10, 2018
12:52Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
